PMC:7073332 / 19236-19635
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 551 | 290-294 | Chemical | denotes | GSEA |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T135 | 131-132 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T136 | 209-210 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T190 | 49-54 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T191 | 266-268 | Chemical | denotes | S4 | http://purl.obolibrary.org/obo/CHEBI_29401 |
| T192 | 331-340 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T117 | 0-399 | Sentence | denotes | We next selected 16 high-confidence repurposable drugs (Fig. 5a and Table 1) against HCoVs using subject matter expertise based on a combination of factors: (i) strength of the network-predicted associations (a smaller network proximity score in Supplementary Table S4); (ii) validation by GSEA analyses; (iii) literature-reported antiviral evidence, and (iv) fewer clinically reported side effects. |